natgillin/translations-raw huggingface dataset:
Ask your doctor or pharmacist for advice on alternative methods of emergency contraception.
Obratite se svom liječniku ili ljekarniku za savjet o alternativnim metodama hitne kontracepcije.
[The information below should be added in this section together with the two tables which follow]
[Informacije u nastavku dodaju se u ovaj dio zajedno s dvama tablicama koje slijede]
[The existing product information shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the agreed wording as provided below]
[Postojeće informacije o lijeku mijenjaju se (uvrštenje, zamjena ili brisanje teksta po potrebi) kako bi odrazile usuglašeni tekst naveden u nastavku]
Pregnancy rate (95% CI) according to weight categories Weight (kg) N total N pregnancies
Stopa trudnoća (95% CI) prema kategorijama tjelesne težine Tjelesna težina (kg) Ukupan broj korisnica
Therefore, <invented name> is still recommended for all women regardless of their weight or BMI.
Stoga se <zaštićeno ime> i dalje preporučuje za sve žene, bez obzira na tjelesnu težinu ili ITM.
In all women, emergency contraception should be taken as soon as possible after unprotected intercourse.
Sve žene hitnu kontracepciju trebaju uzeti što ranije nakon nezaštićenog spolnog odnosa.
Both meta-analyses excluded intake later than 72 hours after unprotected intercourse (i.e. off-label use of levonorgestrel) and women who had further acts of unprotected intercourse.
U obje meta-analize nisu bili uključeni uzimanje kontraceptiva više od 72 sata nakon nezaštićenog spolnog odnosa (tj. neodobrena uporaba levonorgestrela) i žene koje su imale daljnje nezaštićene spolne odnose.
In three WHO studies no trend for a reduced efficacy with increasing body weight/BMI was observed (Table 1), whereas in the two other studies (Creinin et al., 2006 and Glasier et al., 2010) a reduced contraceptive efficacy was observed with increasing body weight or BMI (Table 2).
U trima ispitivanjima Svjetske zdravstvene organizacije nije primijećen trend smanjenja djelotvornosti s porastom tjelesne težine/ITM-a (Tablica 1), dok je u dvama drugim ispitivanjima (Creinin i sur., 2006 te Glasier i sur., 2010) primijećena smanjena djelotvornost kontraceptiva s porastom tjelesne težine ili ITM-a (Tablica 2).
Table 1: Meta-analysis on three WHO studies (Von Hertzen et al., 1998 and 2002; Dada et al., 2010)
Tablica 1: Meta-analiza triju ispitivanja SZO-a (Von Hertzen i sur., 1998 i 2002; Dada i sur., 2010)
Table 2: Meta-analysis on studies of Creinin et al., 2006 and Glasier et al., 2010
Tablica 2: Meta-analiza ispitivanja koja su proveli Creinin i sur., 2006 te Glasier i sur., 2010
In all women, emergency contraception should be taken as soon as possible after unprotected intercourse, regardless of the woman's body weight or BMI.
Sve žene hitnu kontracepciju trebaju uzeti što ranije nakon nezaštićenog spolnog odnosa, bez obzira na tjelesnu težinu ili ITM.
Take special care with <invented name> <strength> tablet
Budite posebno oprezni s <zaštićeno ime> <jačina> tabletama
B. Package leaflet
Dodatak III
[The information below should be deleted together with the table] In clinical trials, contraceptive efficacy was reduced in women weighing 75 kg or more and levonorgestrel was not effective in women who weighed more than 80 kg (see sections 4.2 and 4.4).
[Informacije u nastavku se brišu, zajedno s tablicom] U kliničkim je ispitivanjima učinkovitost kontraceptiva bila smanjena u žena tjelesne težine od 75 kg ili više, a levonogestrel nije bio učinkovit u žena tjelesne težine veće od 80 kg (vidjeti dijelove 4.2 i 4.4).
Limited and inconclusive data suggest that there may be reduced efficacy of <invented name> with increasing body weight or body mass index (BMI) (see section 5.1).
Ograničeni podaci koji ne dopuštaju donošenje konačnih zaključaka upućuju na to da se djelotvornost <zaštićeno ime> može smanjivati s porastom tjelesne težine ili indeksa tjelesne mase (ITM) (vidjeti dio 5.1).
Studies suggest that <invented name> is less effective in women weighing 75 kg or more and not effective in women weighing more than 80 kg.
Ispitivanja upućuju na to da je lijek <zaštićeno ime> manje učinkovit u žena tjelesne težine od 75 kg ili više te da nije učinkovit u žena tjelesne težine veće od 80 kg.
There is some evidence that <invented name> may be less effective with increasing body weight or body mass index (BMI), but these data were limited and inconclusive.
Neki dokazi upućuju na to da se djelotvornost <zaštićeno ime> može smanjivati porastom tjelesne težine ili indeksa tjelesne mase (ITM), no ti su podaci nedostatni za donošenje konačnih zaključaka.
For Levonorgestrel-containing emergency contraceptive medicinal products A. Summary of product characteristics
Za hitne kontraceptive koji sadrže levonorgestrel A.
- if you weigh 75 kg or more (see “What <invented name> <strength> tablet is and what it is used for” for further details)
- ako imate 75 kg ili više (za više informacija pogledajte dio
There is limited and inconclusive data on the effect of high body weight/high BMI on the contraceptive efficacy.
Podaci o utjecaju velike tjelesne težine/visokog ITM-a na učinkovitost kontraceptiva su ograničeni i nedostatni za donošenje konačnih zaključaka.
Annex III Amendments to relevant sections of the summary of product characteristics and package leaflet
Izmjene odgovarajućih dijelova sažetaka opisa svojstava lijeka i uputa o lijeku
BEFORE YOU USE <invented name> <strength> TABLET
<zaštićeno ime> <jačina> TABLETE
[the phrase below should be deleted from this section] Special population: body weight 75 kg or more
Posebne populacije: tjelesna težina od 75 kg ili više
- If you are more than 3 months pregnant.
- Ako ste dulje od 3 mjeseca trudni.
Al/Al blisters:
Al/Al blisteri:
Cumulative urinary excretion is < 1% of dose.
Kumulativna urinarna ekskrecija je <1% doze.
250 tablets
250 tableta
Currently available data are described in section 5.1 and 5.2 but no recommendation on a posology can be made.
Trenutno dostupni podaci opisani su u dijelovima 5.1 i 5.2, ali se ne mogu dati preporuke za doziranje.
The tablets should be swallowed with some water or other non-alcoholic drink.
Tablete treba progutati s malo vode ili s drugim bezalkoholnim pićem.
(It is also better to avoid Telmisartan Actavis in early pregnancy - see pregnancy section.)
(Također je bolje izbjegavati Telmisartan Actavis u ranoj trudnoći - vidjeti dio o trudnoći.)
You can take Telmisartan Actavis with or without food.
Možete uzimati Telmisartan Actavis sa ili bez hrane.
Thus it is important to regularly measure blood pressure to verify if it is within the normal range.
Stoga je važno redovito mjeriti krvni tlak i pratiti je li unutar normalnog raspona.
If you forget to take your medicine you should take the dose as soon as you remember on the same day.
Ako ste zaboravili uzeti lijek, isti dan uzmite svoju dozu čim se sjetite.
It is important that you take Telmisartan Actavis every day until your doctor tells you otherwise.
Telmisartan Actavis svaki dan, dok Vam liječnik ne kaže drugačije.
The safety data from this study in patients aged 6 to < 18 years appeared generally similar to that observed in adults.
Podaci o sigurnosti iz ovog ispitivanja na bolesicima u dobi od 6 do < 18 godina starosti smatrale su se općenito sličnima onima primijećenima kod odraslih osoba.
If you feel dizzy or tired, do not drive or use machines.
Ako osjećate omaglicu ili umor, ne upravljajte vozilima ili strojevima.
When considering raising the dose, it must be borne in mind that the maximum antihypertensive effect is generally attained four to eight weeks after the start of treatment (see section 5.1).
Kada se razmatra povišenje doze, mora se uzeti u obzir da se maksimalni antihipertenzivni učinak općenito postiže četiri do osam tjedana nakon početka liječenja (vidjeti dio 5.1).
If you have the impression that the effect of Telmisartan Actavis is too strong or too weak, talk to your doctor or pharmacist.
Ako mislite da je učinak lijeka Telmisartan Actavis prejak ili preslab, razgovarajte sa svojim liječnikom ili ljekarnikom.
Telmisartan is largely bound to plasma protein (> 99.5%), mainly albumin and alpha-1 acid glycoprotein.
Telmisartan se uvelike veže na proteine plazme (>99,5%), uglavnom albumin i alfa-1 kiselinski glikoprotein.
- If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Telmisartan Actavis” and “Warnings and precautions”).
- Ako uzimate ACE inhibitor ili aliskiren (vidjeti također informacije pod naslovima „Nemojte uzimati Telmisartan Actavis“ i „Upozorenja i mjere opreza“).
By 3 hours after administration plasma concentrations are similar whether telmisartan is taken fasting or with food.
Do 3 sata nakon primjene, koncentracije u plazmi su slične bez obzira uzima li se telmisartan natašte ili s hranom.
The maximum plasma concentration (Cmax) and, to a smaller extent, the area under the plasma concentration-time curve (AUC) increase disproportionately with dose.
Maksimalna koncentracija u plazmi (Cmax) i, u manjoj mjeri, površina ispod krivulje koncentracije u plazmi-vrijeme (AUC), povećava se disproporcionalno s dozom.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 30.09.2010
Datum prvog odobrenja: 30.09.2010.
See also information under the heading “Do not take Telmisartan Actavis”.
Vidjeti također informacije pod naslovom „Nemojte uzimati Telmisartan Actavis“.
Your doctor will normally advise you to stop taking Telmisartan Actavis before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Telmisartan Actavis.
Liječnik će Vam obično savjetovati da prestanete uzimati Telmisartan Actavis prije nego ostanete trudni ili čim saznate da ste trudni te će Vam savjetovati uzimanje drugog lijeka umjesto lijeka Telmisartan Actavis.
The occurrence of hyperkalaemia depends on associated risk factors.
Pojava hiperkalemije ovisi o udruženim čimbenicima rizika.
In case of surgery or anaesthesia, you should tell your doctor that you are taking Telmisartan Actavis.
U slučaju kirurškog zahvata ili anestezije, trebate obavijestiti svog liječnika da uzimate Telmisartan
Whilst there is no controlled epidemiological data on the risk with angiotensin II receptor antagonists, similar risks may exist for this class of drugs.
Iako nema kontroliranih epidemioloških podataka o riziku uz antagoniste receptora angiotenzina II, slični rizici mogu postojati za ovu skupinu lijekova.
Telmisartan is characterised by biexponential decay pharmacokinetics with a terminal elimination half-life of > 20 hours.
Za telmisartan je karakteristična bieksponencijalna farmakokinetika raspada, s terminalnim poluvremenom eliminacije od >20 sati.
Al/Al blisters: Store in the original package in order to protect from light.
Al/Al blisteri: Čuvati u originalnom pakiranju radi zaštite od svjetlosti.
Do not use this medicine after the expiry date which is stated on the carton, bottle or blister after “EXP”.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji, boci ili blisteru iza EXP/“Rok valjanosti“.
Insomnia, depression
Nesanica, depresija Anksioznost
The overall incidence of adverse reactions reported with telmisartan was usually comparable to placebo (41.4% vs 43.9%) in placebo controlled trials in patients treated for hypertension.
Ukupna incidencija nuspojava zabilježenih s telmisartanom bila je uobičajeno usporediva s placebom (41,4% u odnosu na 43,9%), u placebo kontroliranim ispitivanjima u bolesnika liječenih zbog hipertenzije.
HDPE tablet container:
HDPE spremnik s tabletama:
The incidence of the primary endpoint was similar in the telmisartan (16.7%) and ramipril (16.5%) groups.
Incidencija primarnog ishoda bila je slična u skupinama na telmisartanu (16,7%) i ramiprilu (16,5%).
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Detaljne informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove http://www.ema.europa.eu/.
1,2,3,4: for further descriptions, please see sub-section 4 ”Description of selected adverse reactions”.
1, 2, 3, 4: za daljnje opise, molimo vidjeti odjeljak 4 „Opis odabranih nuspojava“.
OTHER SPECIAL WARNING(S), IF NECESSARY Contains desiccant, do not eat.
DRUGO(A) POSEBNO(A) UPOZORENJE(A), AKO JE POTREBNO Sadrži sredstvo za sušenje koje se ne smije jesti.
14 tablets 28 tablets 30 tablets 56 tablets 84 tablets 90 tablets 98 tablets 100 tablets
14 tableta 28 tableta 30 tableta 56 tableta 84 tablete 90 tableta 98 tableta 100 tableta
Gender differences in plasma concentrations were observed, Cmax and AUC being approximately 3-and 2-fold higher, respectively, in females compared to males.
Uočene su razlike obzirom na spol u koncentracijama u plazmi, s Cmax i AUC oko 3 odnosno 2 puta višima u žena u usporedbi s muškarcima.
*The event may have happened by chance or could be related to a way that telmisartan works that is currently not known.
*Događaj može biti slučajan ili može biti povezan s načinom djelovanja telmisartana koji trenutno nije poznat.
Talk to your doctor before taking Telmisartan Actavis: - if you are taking digoxin.
Obratite se svom liječniku prije nego uzmete Telmisartan Actavis: - ako uzimate digoksin.
What Telmisartan Actavis contains - The active substance is telmisartan.
Što Telmisartan Actavis sadrži - Djelatna tvar je telmisartan.
High blood pressure, if not treated, can damage blood vessels in several organs which could lead sometimes to heart attacks, heart or kidney failure, strokes or blindness.
Visoki krvni tlak, ako se ne liječi, može oštetiti krvne žile u različitim organima, što ponekad može dovesti do srčanog udara, zatajenja srca ili bubrega, moždanog udara ili sljepoće.
When telmisartan is taken with food, the reduction in the area under the plasma concentration-time curve (AUC0-∞) of telmisartan varies from approximately 6% (40 mg dose) to approximately 19% (160 mg dose).
Kada se telmisartan uzima s hranom, smanjenje površine ispod krivulje koncentracije telmisartana u plazmi-vrijeme (AUC0-∞) varira od oko 6% (doza 40 mg) do oko 19% (doza 160 mg).
Tablet container: 30 and 250 tablets.
Spremnik s tabletama: 30 i 250 tableta.
The mean absolute bioavailability for telmisartan is about 50%.
Srednja vrijednost apsolutne bioraspoloživosti telmisartana je oko 50%.
Pharmacokinetic studies in patients with hepatic impairment showed an increase in absolute bioavailability up to nearly 100 %.
Oštećenje jetre Farmakokinetička ispitivanja u bolesnika s oštećenjem jetre pokazala su porast apsolutne bioraspoloživosti do gotovo 100%.
Total plasma clearance (Cltot) is high (approximately 1,000 ml/min) compared with hepatic blood flow (about 1,500 ml/min).
Ukupni klirens plazme (Cltot) je velik (oko 1000 ml/min) u usporedbi s protokom krvi u jetri (oko 1500 ml/min).
- Heart trouble.
- Problemi sa srcem.
Do not take Telmisartan Actavis - if you are allergic to telmisartan or any other ingredients of this medicine (listed in section 6).
Nemojte uzimati Telmisartan Actavis - Ako ste alergični na telmisartan ili neki drugi sastojak ovog lijeka (navedene u dijelu 6).
If you accidentally take too many tablets ask your doctor what to do or contact your nearest hospital emergency department immediately.
Ako ste slučajno uzeli previše tableta, odmah se obratite svom liječniku ili u hitnu službu najbliže bolnice.
Telmisartan Actavis is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
Telmisartan Actavis se ne preporučuje dojiljama te Vaš liječnik može odabrati drugo liječenje za Vas ako želite dojiti, osobito ako je Vaše dijete novorođenče ili je prerano rođeno.
This is confirmed by trough to peak ratios consistently above 80% seen after doses of 40 and 80 mg of telmisartan in placebo controlled clinical studies.
Ovo je potvrđeno omjerima minimalnih do maksimalnih vrijednosti koje su konstantno bile iznad 80% nakon doza od 40 i 80 mg telmisartana u placebom kontroliranim kliničkim ispitivanjima.
Volume and/or sodium depletion should be corrected prior to administration of Telmisartan Actavis .
Deplecija volumena i/ili natrija se mora korigirati prije primjene lijeka Telmisartan Actavis.
The risk is particularly high in combination with potassium sparing-diuretics and when combined with salt substitutes containing potassium.
Rizik je osobito visok u kombinaciji s diureticima koji štede kalij i u kombinaciji s nadomjescima soli koje sadrže kalij.
As with other medicinal products acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia (see section 4.4).
Poput ostalih lijekova koji djeluju na sustav renin-angiotenzin-aldosteron, telmisartan može izazvati hiperkalemiju (vidjeti dio 4.4).
The use of Telmisartan Actavis in children and adolescents up to the age of 18 years is not recommended.
Primjena lijeka Telmisartan Actavis u djece i adolescenata do dobi od 18 godina se ne preporučuje.
At the beginning of the preventive therapy with Telmisartan Actavis 80 mg, blood pressure should be frequently monitored.
Na početku preventivnog liječenja lijekom Telmisartan Actavis od 80 mg, krvni tlak treba redovito pratiti.
(See section 5.3).
i 5.1).
- Diuretics ('water tablets'), especially if taken in high doses together with Telmisartan Actavis,
- Diuretici („tablete za mokrenje“), osobito ako se uzimaju visoke doze zajedno s lijekom
Telmisartan Actavis may be less effective in lowering the blood pressure in black patients.
Telmisartan Actavis može biti manje učinkovit u snižavanju krvnog tlaka u bolesnika crne rase.
What Telmisartan Actavis is and what it is used for
Što je Telmisartan Actavis i za što se koristi
How to store Telmisartan Actavis Contents of the pack and other information
Kako čuvati Telmisartan Actavis Sadržaj pakiranja i druge informacije
There is no experience regarding the administration of Telmisartan Actavis in patients with recent kidney transplantation.
Ne postoji iskustvo u vezi primjene lijeka Telmisartan Actavis u bolesnika kojima je nedavno transplantiran bubreg.
Pharmacotherapeutic group: Angiotensin II Antagonists, plain, ATC code: C09CA07.
5.1 Farmakodinamička svojstva Farmakoterapijska skupina: Antagonisti angiotenzina II, čisti, ATK oznaka: C09CA07.
What you need to know before you take Telmisartan Actavis
Što morate znati prije nego počnete uzimati Telmisartan Actavis
Some people feel dizzy or tired when taking Telmisartan Actavis.
Neki ljudi osjećaju omaglicu ili umor kada uzimaju Telmisartan Actavis.
This applies especially to the medicines listed below taken at the same time with Telmisartan Actavis
Ovo se osobito odnosi na lijekove koji su navedeni u nastavku, a uzimaju se istodobno s lijekom Telmisartan Actavis:
As observed for angiotensin converting enzyme inhibitors, telmisartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in nonblacks, possibly because of higher prevalence of low-renin states in the black hypertensive population.
Kao što je uočeno za inhibitore angiotenzin konvertirajućeg enzima, telmisartan i drugi antagonisti angiotenzina su manje učinkoviti u snižavanju krvnog tlaka u osoba crne rase nego u osoba koje nisu crne rase, možda zbog veće prevalencije stanja sa sniženim vrijednostima renina u populaciji crne rase s hipertenzijom.
For reduction of cardiovascular events, the usual dose of Telmisartan Actavis is one 80 mg tablet once a day.
Za smanjivanje kardiovaskularnih događaja, uobičajena doza lijeka Telmisartan Actavis je jedna tableta od 80 mg, jednom dnevno.
Other medicines and Telmisartan Actavis
Drugi lijekovi i Telmisartan Actavis
The effect of Telmisartan Actavis may be reduced when you take NSAIDs (non steroidal anti-inflammatory drugs, e.g. aspirin or ibuprofen) or corticosteroids.
Učinak lijeka Telmisartan Actavis se može smanjiti kada uzimate NSAIL (nesteroidne protupalne lijekove, npr. aspirin ili ibuprofen) ili kortikosteroide.
Angiotensin II is a substance produced in your body, which causes your blood vessels to narrow, thus increasing your blood pressure.
Angiotenzin II je tvar koja se stvara u Vašem tijelu i dovodi do sužavanja krvnih žila, čime se povisuje krvni tlak.
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10); često (≥1/100 do <1/10); manje često (≥1/1000 do <1/100); rijetko (≥1/10 000 do
Telmisartan Actavis is contraindicated in patients with severe hepatic impairment (see section 4.3).
Telmisartan Actavis je kontraindiciran u bolesnika s teškim oštećenjem jetre (vidjeti dio 4.3).
Close-monitoring of serum potassium in at risk patients is recommended (see section 4.5).
Preporučuje se pažljivo pratiti kalij u serumu rizičnih bolesnika (vidjeti dio 4.5).
Telmisartan Actavis is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section 4.3) since telmisartan is mostly eliminated with the bile.
Telmisartan Actavis se ne smije davati bolesnicima s kolestazom, bilijarnom opstrukcijom ili teškim oštećenjem jetre (vidjeti dio 4.3), s obzirom da se telmisartan uglavnom eliminira putem žuči.
You should consult with your doctor if you need to adjust the dose of your other medicine while taking Telmisartan Actavis.
Potrebno je posavjetovati se s liječnikom ako trebate prilagodbu doze drugih lijekova dok uzimate Telmisartan
MINIMUM PARTICULARS TO APPEAR ON BLISTERS Blister
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER Blister
If any of the above applies to you, tell your doctor or pharmacist before taking Telmisartan Actavis.
Ako se nešto od prethodno navedenog odnosi na Vas, obavijestite liječnika ili ljekarnika prije početka uzimanja lijeka Telmisartan Actavis.
In dogs renal tubular dilation and atrophy were observed.
U pasa su uočene renalna tubularna dilatacija i atrofija.
Hepatic function abnormal / liver disorder
Abnormalna funkcija jetre / poremećaj rada jetre
There are no adequate data from the use of Telmisartan Actavis in pregnant women.
Ne postoje odgovarajući podaci o primjeni lijeka Telmisartan Actavis u trudnica.
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5% CI 0.931.10, p (non-inferiority) = 0.0019 at a margin of 1.13).
Omjer hazarda za telmisartan u odnosu na ramipril bio je 1,01 (97,5% CI 0,93 - 1,10, p (neinferiornost) = 0,0019 na granici od 1,13).
Haemoglobin decreased, blood uric acid increased, hepatic enzyme increased, blood creatine phosphokinase increased
Sniženi hemoglobin, povišene vrijednosti mokraćne kiseline u krvi, povišeni jetreni enzimi, povišena kreatin-fosfokinaza u krvi
Telmisartan Actavis is also used to reduce cardiovascular events (i.e. heart attack or stroke) in adults who are at risk because they have a reduced or blocked blood supply to the heart or legs, or have had a stroke or have high risk diabetes.
Telmisartan Actavis se također primjenjuje za smanjivanje kardiovaskularnih događaja (tj. srčanog udara ili moždanog udara) u rizičnih odraslih osoba koje imaju smanjenu ili prekinutu opskrbu krvlju srca ili nogu, ili su imale moždani udar, ili imaju šećernu bolest s visokim rizikom za oštećenje organa.
Angiotensin II receptor antagonists should not be initiated during pregnancy.
Primjena antagonista receptora angiotenzina II ne smije se započinjati tijekom trudnoće.
Symptoms: The most prominent manifestations of telmisartan overdose were hypotension and tachycardia; bradycardia dizziness, increase in serum creatinine, and acute renal failure have also been reported.
Simptomi: Najizraženije manifestacije predoziranja telmisartanom bile su hipotenzija i tahikardija; također su zabilježeni bradikardija, omaglica, porast kreatinina u serumu i akutno zatajenje bubrega.
In patients with liver problems the usual dose should not exceed 40 mg once daily.
U bolesnika s oštećenom jetrom, uobičajena doza ne smije prelaziti 40 mg jednom dnevno.